课题基金 / 基金详情

Structure-Based Characterization of gp120 Non-V3 Variable Loop Epitopes

Structure-Based Characterization of gp120 Non-V3 Variable Loop Epitopes
gp120 非 V3 可变环表位的基于结构的表征
批准号:
8121572
负责人:
TIMOTHY J CARDOZO
金额:
$58.57万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-10 至 2013-08-31

项目摘要

项目成果

TIMOTHY J CARDOZO的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): We propose unconventional, unique and exceptionally novel methods to uncover the structure of broadly neutralizeable epitopes in the variable loops of gp120. This work challenges the standard paradigm that the variable loops of gp120 are too dynamic and variable to have conserved epitopes useful in a vaccine. We were able to devise a novel computational de-noising approach to the sequence and structural variability in these loops and have a high likelihood of identifying the first broadly neutralizing antibodies targeting epitopes in V1, V2 V4 and/or V5. We are confident of attaining this significant outcome based on our preliminary results with the V3 loop. The research group and the proposed research is uniquely suited to the stated goals of the HIT-IT initiative, rather than a conventional research grant (R01) application. This is because we have a proven track record of this kind of innovation targeting the V3 loop, and because the research addresses a problem that is both crucial to an HIV vaccine and simultaneously thought currently to be too challenging to address. All prior failed HIV vaccines have targeted sequence conserved and non-gp120 determinants in the virus. This is primarily because the dynamic, sequence variable surface loops of gp120 are considered too challenging to dissect for hidden broadly neutralizing antibody epitopes. This research proposes a highly innovative tactic to meet this challenge and produce the first structure-based design of immunogens mimicking broadly neutralizing epitopes in the variable loops V1, V2, V4 and V5.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Discovery of novel openers of the understudied human drug target Kir6.1
ADE-minimized COVID-19 vaccine via epitope focusing and anti-inflammatory innate immunity
Epitope optimization for heterologous prime-boost HIV vaccines
Stabilizing nuclear p27kip1 as a therapeutic target for endometrial cancer
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2022
  • 负责人:
    王亚伟
  • 依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究